{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:45:36Z","timestamp":1787013936378,"version":"build-2736575974"},"reference-count":46,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T00:00:00Z","timestamp":1520899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007903","name":"Bloodwise","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    The treatment landscape for mantle cell lymphoma (\n                    <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>\n                    ) has changed dramatically in recent years, with findings from clinical trials reporting improvements in survival. Data on the general patient population are, however, sparse; and it is unclear whether the effects observed in clinical trials have translated into the real\u2010world setting. To investigate this, we examined first\u2010line and relapsed\/refractory (\n                    <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n                    ) disease management in 335\n                    <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>\n                    patients diagnosed between 2004 and 2015 in an established population\u2010based patient cohort, along with data on demographic, diagnostic and prognostic factors. Marked treatment and survival changes were observed; first\u2010line rituximab immunotherapy, for example, increased from 32% to 86% over the 11\u2010year period, and median survival increased from 2\u00b70\u00a0years among those first treated in 2004\u20132011 to 3\u00b75\u00a0years among those treated in 2012\u20132015. Outcomes for\n                    <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n                    disease also improved, from 8\u00a0months in 2004\u20132011 to 16\u00b78\u00a0months in 2012\u20132015, coinciding with the introduction of agents, such as bendamustine and ibrutinib. Encouragingly, improvements were seen across all ages; 1\u2010year overall survival among patients over 70\u00a0years treated for\n                    <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n                    disease almost doubled. Our analyses underscore the importance of monitoring the impact of treatment changes in the real\u2010world setting.\n                  <\/jats:p>","DOI":"10.1111\/bjh.15170","type":"journal-article","created":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T06:43:04Z","timestamp":1521096184000},"page":"215-228","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the\n                    <scp>UK<\/scp>\n                    's Haematological Malignancy Research Network (\n                    <scp>HMRN<\/scp>\n                    )"],"prefix":"10.1111","volume":"181","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1111-966X","authenticated-orcid":false,"given":"Alexandra","family":"Smith","sequence":"first","affiliation":[{"name":"Epidemiology &amp; Cancer Statistics Group Department of Health Sciences University of York York UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7603-3704","authenticated-orcid":false,"given":"Eve","family":"Roman","sequence":"additional","affiliation":[{"name":"Epidemiology &amp; Cancer Statistics Group Department of Health Sciences University of York York UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Appleton","sequence":"additional","affiliation":[{"name":"Epidemiology &amp; Cancer Statistics Group Department of Health Sciences University of York York UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Howell","sequence":"additional","affiliation":[{"name":"Epidemiology &amp; Cancer Statistics Group Department of Health Sciences University of York York UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rod","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology St James's University Hospital Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Burton","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology St James's University Hospital Leeds UK"},{"name":"Haematological Malignancy Diagnostic Service St James's University Hospital Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Patmore","sequence":"additional","affiliation":[{"name":"Queen's Centre for Oncology and Haematology Hull and East Yorkshire Hospitals Cottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,3,13]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.587560"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-559930"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00366-5"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-2164-2"},{"key":"e_1_2_7_6_1","unstructured":"Cancer Research UK Cancer Survival Group 2017.UK life tables [WWW Document]. UK Life Tables. URLhttp:\/\/csg.lshtm.ac.uk\/tools-analysis\/uk-life-tables\/(accessed26 January 2018)."},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.656628"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2016.1127761"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.119115"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00667-4"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx223"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2380"},{"key":"e_1_2_7_13_1","unstructured":"Eurostat 2013.Revision of the European Standard Population \u2010 Report of Eurostat's task force \u2010 2013 edition[WWW Document]. URLhttp:\/\/ec.europa.eu\/eurostat\/web\/products-manuals-and-guidelines\/-\/KS-RA-13-028(accessed 26 January 2018)."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.047357"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.8435"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.551154"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.8387"},{"key":"e_1_2_7_20_1","first-page":"1","article-title":"Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop","author":"Kahl B.S.","year":"2017","journal-title":"Leukaemia & Lymphoma"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12308-009-0036-x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200920"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704466"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2015.05.006"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701769"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.6745"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2049-5"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.034264"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30451-2"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.6121"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.05.008"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12046"},{"key":"e_1_2_7_33_1","unstructured":"National Comprehensive Cancer Network 2017.NCCN clinical practice guidelines in oncology. B\u2010cell lymphomas. Version 7.2017 [WWW Document]. URLhttps:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf(accessed 26 January 2018)."},{"key":"e_1_2_7_34_1","unstructured":"NICE 2016.Non\u2010Hodgkin's lymphoma: diagnosis and management: NICE guideline [NG52].National Institute for Health and Care Excellence London UK. [WWW Document]. URLhttps:\/\/www.nice.org.uk\/guidance\/ng52?unlid=88910979820161130132913(accessed 13 December 2016)."},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00472-6"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.128710"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.7501"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.11.002"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk152"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.450"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.94"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/17843286.2017.1293328"},{"key":"e_1_2_7_45_1","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1182\/blood.V128.22.1802.1802","article-title":"Maintenance Therapy for Patients with Mantle Cell Lymphoma (MCL) \u2010 a Systematic Review and Meta\u2010Analysis of Randomized Controlled Trials (RCTs)","volume":"128","author":"Vidal L.","year":"2016","journal-title":"Blood"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00438-6"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.825903"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15170","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T05:33:06Z","timestamp":1695533586000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,13]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1111\/bjh.15170"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15170","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,13]]},"assertion":[{"value":"2017-11-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}